HDAC6-selective inhibitors (ricolinostat and citarinostat) enhance the anti-tumor effects of CTLs in melanoma patients by decreasing the expression of Forkhead Box P3 (FOXP3) to suppress the functions of regulatory T cells (Laino et al., 2019, Figure 5B). This evidence concerns the gene HDAC6 and melanoma.